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Psoriasis and Cardiovascular Risk: 
Strength in Numbers
Joel M. Gelfand1,2, Rahat S. Azfar1,2,3 and Nehal N. Mehta2,4
In this issue, Wakkee and colleagues report a self-described exploratory cohort 
study and conclude that psoriasis may not be an independent risk factor for 
ische mic heart disease (IHD) hospitalization and that there is only a slight and 
borderline increased risk of ischemic heart disease among psoriasis patients. 
This negative result should be interpreted in light of the study’s limitations, 
the complex relationship among levels of psoriasis severity, patient age, and 
cardiovascular (CV) risk, and the context of the rapidly growing literature.
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When interpreting a negative study, 
two basic principles must be evalu-
ated. First, are the data on exposure, 
outcome, and covariables (such as con-
founders) valid? By valid, we mean does 
the study measure what it intends to 
measure? Database studies, especially 
those using administrative data in which 
the primary purpose is for payment, 
are prone to error in that the electronic 
code entered by a health care provider 
or administrator may not reflect the 
true clinical state of the patient (Strom, 
2005). Such errors (called misclassi-
fication bias) may mask true associa-
tions and yield false-negative results. 
Multiple approaches are necessary to 
validate a database code, including 
medical-record review to determine the 
predictive value of an electronic code 
to reflect the true clinical state (Rawson 
and D’Arcy, 1998). For example, in the 
General Practice Research Database 
(GPRD), the positive predictive value of 
a psoriasis code was about 90%, based 
on a medical record review conducted 
by general practitioners 3–4 years after 
the entry of diagnostic codes (Neimann 
et al., 2006). Similarly, other investiga-
tors have shown in the GPRD that the 
positive predictive value of an acute 
myocardial infarction (MI) code is 90% 
based on a review of medical-record 
data that included factors such as diag-
nostic electrocardiogram changes, 
chest pain presentations, and cardiac 
enzymes (Meier et al., 1998; Hammad 
et al., 2008).
Wakkee and colleagues (2010, 
this issue) do not present data on the 
positive predictive value of their coding 
algorithm to measure the exposure of 
interest (psoriasis) or the outcome of 
interest (hospitalizations for ischemic 
heart disease (IHD)) using the gold 
standard of medical-record review. 
Thus, one cannot exclude misclas-
sification bias as a source of error 
that explains their negative results. 
Furthermore, Wakkee et al. did not 
report the results of their multivariable 
model, so we are unable to determine 
whether their approach was able to con-
firm the expected relationships between 
cardiovascular (CV) risk factors and 
hospitalization for acute IHD (von Elm 
et al., 2007).
The second basic principle is statisti-
cal error. The key question is whether a 
study has the statistical power to detect 
a clinically meaningful association, 
if one truly exists. Wakkee et al. show 
in Table 2 of their article that the haz-
ard ratios for acute IHD hospitalization 
(primary end point) and acute myocar-
dial infarction (secondary end point), 
adjusted for prior use of antihyper-
tensive, antidiabetic, and lipid-lowering 
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drugs, and a measure of health utiliza-
tion were 1.05 (95% confidence inter-
val 0.95 to 1.17) and 0.94 (0.80, 1.11), 
respectively. However, in the general 
population, the majority of patients 
(about 80%) have mild psoriasis (≤2% 
body surface area) and a small minority 
(about 5%) have severe disease (>10% 
body surface area), meaning that the 
analysis is driven by patients with mild 
psoriasis (Stern et al., 2004; Kurd and 
Gelfand, 2009). Although their primary 
finding was not statistically significant, 
their point estimate of the association of 
psoriasis overall (e.g., not restricted to 
severe disease) with acute IHD is simi-
lar to our own results and to the results 
of others (Gelfand et al., 2006; Brauchli 
et al., 2009). This small association 
requires additional studies to confirm, 
but it could be important from a public 
health point of view because an estimat-
ed 125 million people are affected by 
psoriasis worldwide (National Psoriasis 
Foundation, http://www.psoriasis.org/
netcommunity/learn_statistics).
Of special interest, however, is the 
impact of severe psoriasis on CV risk. 
Wakkee and colleagues (2010) do not 
report the hazard ratio with 95% con-
fidence interval in patients who have 
severe psoriasis (such as patients requir-
ing treatment with systemic drugs or 
phototherapy). Thus, we cannot deter-
mine whether the authors’ study had 
sufficient statistical power to detect a 
meaningful association between severe 
psoriasis and acute IHD, nor can we 
determine whether their point esti-
mate of association was similar to that 
of other studies (von Elm et al., 2007). 
Finally, given that the relative risk of CV 
events is greatest in younger patients 
with severe disease, this finding should 
be accounted for in multivariable 
models (Mallbris et al., 2004; Gelfand 
et al., 2006; Brauchli et al., 2009). This 
finding, referred to as effect modifica-
tion or statistical interaction, is difficult 
to detect because of limit ations of sta-
tistical power. Wakkee and colleagues 
attempted to evaluate effect modification 
by stratification on an arbitrarily select-
ed age (i.e., 65 years); however, this 
approach may be too simplistic because 
age is the most important risk factor for 
CV disease. Importantly, athero sclerosis 
and IHD are diseases of aging, and CV 
risk follows a quadratic, hyperbolic curve 
in which the competing risk of age, espe-
cially after age 50, outweighs accelerat-
ing risk factors for athero sclerosis such as 
the metabolic syndrome (Wilson et al., 
1998; Gelber et al., 2008). Therefore, 
we cannot determine whether the lack 
of effect modification by age reported 
by Wakkee is valid, because it may be 
attributable to a lack of statistical power 
or to selecting an incorrect age on which 
to dichotomize.
All good science depends on other 
investigators confirming the findings 
using robust approaches. Older epi-
demiological approaches, which were 
more sensitive to bias, have yielded 
conflicting findings (McDonald, 1989). 
For example, Stern compared the rates 
of CV mortality in a cohort of patients 
with generally severe psoriasis derived 
from a clinical trial of psoralen plus 
UVA at tertiary-care medical centers 
with those in the general US popula-
tion and found that the point estimate 
for psoriasis was actually protective for 
CV death but not statistically significant 
(standardized mortality ratio for CV 
mortality, 0.83 (90% confidence inter-
val 0.7–1.0)) (Stern and Lange, 1988). 
The psoralen plus UVA clinical trial 
patients, however, are not representa-
tive of the US population (e.g., selection 
bias), and the problem is compounded 
by the fact that CV mortality rates vary 
widely (by twofold or greater) across the 
United States (Labarthe, 1998; Rothman 
et al., 2008). In sum, non-population-
based studies that do not have appropri-
ate internal controls can be difficult to 
interpret.
In contrast, modern epidemio-
logical approaches using population-
based methods, which minimize bias 
and enhance generalizability, have 
found similar point estimates for the 
adjusted relative risk of coronary heart 
events reported by Wakkee et al. (hos-
pitalization for IHD), Brauchli (MI), and 
Gelfand (MI) in psoriasis patients over-
all (Rothman and Greenland, 1998; 
Gelfand et al., 2006; Brauchli et al., 
2009). Moreover, as shown by Brauchli 
et al. (2009) and our group (Gelfand 
et al., 2006), the point estimate of the 
adjusted relative risk of MI in severe 
psoriasis (based on treatment patterns) 
is clinically important and exceeds or 
is similar to the relative risk of MI con-
ferred by major CV risk factors such 
hypertension, diabetes, and hyper-
lipidemia. To put this in perspective, 
the annual risk of a patient with severe 
psoriasis (based on treatment history) 
who is in his or her 40s having an MI 
that is attributable to psoriasis and not 
to traditional CV risk factors is estimated 
to be about eight times greater than that 
patient’s risk of developing a melanoma 
(Gelfand et al., 2006; SEER, 2009).
Other investigators, using vary-
ing approaches and populations, have 
recently shown that severe psoriasis is 
an independent risk factor for athero-
sclerotic CV disease as defined by out-
comes such as database-derived codes, 
imaging of coronary and carotid arter-
ies, and measurements of endothelial 
function and arterial stiffness (Ludwig et 
al., 2007; Balci et al. 2008; El-Mongy et 
al., 2009; Gisondi et al., 2009; Gladman 
et al., 2009; Prodanovich et al., 2009). 
Wakkee et al. (2010) note that informa-
tion bias (e.g., psoriasis patients may 
be screened more carefully for CV dis-
ease) may explain the positive associa-
tions; however, this is unlikely. First, in 
our studies, analyses limited to patients 
seen regularly by a general practitio-
ner had minimal impact on the point 
estimates (Gelfand et al., 2006, 2009). 
Wakkee et al. adjusted for this poten-
tial bias by including the total number 
of hospitalizations (except for CV dis-
eases) in the 6 months before cohort 
entry, in addition to adjusting for pre-
scriptions for hypertension, hyperlipi-
demia, and diabetes. Although adjust-
ing for prior health care utilization did 
not appear to meaningfully confound 
the association (e.g., the point estimates 
changed by less than 10%), it is impor-
tant to note that this approach may not 
be appropriate for assessing informa-
tion bias, because prior use of health 
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Database conclusions, 
using information 
gathered for different 
reasons, must be 
interpreted with care.
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care services could be in the causal 
pathway of the association. For exam-
ple, diabetes is associated with higher 
use of health care utilization; however, 
diabetes is still a risk factor for MI and 
adjusting for prior health care utiliza-
tion is only likely to falsely attenuate 
this association. Second, MI is a rela-
tively hard end point, with our results 
extending to CV mortality as well, and 
the magnitude of association of severe 
psoriasis with MI and CV mortality is 
similar to or exceeds that of the associa-
tion of traditional major CV risk factors 
(Mehta et al., 2009). It seems unlikely 
that general practitioners look more 
carefully for MI in psoriasis patients than 
in patients with diabetes and hyperten-
sion, and CV mortality would be robust 
to observation bias. Furthermore, other 
studies that have used diagnostic testing 
in psoriasis and control patients (e.g., 
coronary artery computed tomography 
scans) would not be subject to detec-
tion bias of the outcome, and they have 
similarly found psoriasis to be an inde-
pendent risk factor for CVD (Ludwig et 
al., 2007; Balci et al., 2008; El-Mongy 
et al., 2009; Gisondi et al., 2009).
Wakkee and colleagues (2010) 
also raise the important point that 
incompletely measured or unknown 
confounders can explain the associa-
tions we and others have observed. This 
possibility is difficult to exclude, but 
it appears less likely, because several 
studies that have looked at CV disease 
in small cross-sectional studies using 
well-defined cases and controls have 
confirmed the independent association, 
even when tightly controlling for con-
founding through direct measurement of 
risk factors (Ludwig et al., 2007; Balci et 
al., 2008; El-Mongy et al., 2009; Gisondi 
et al., 2009). Moreover, we have shown 
in studies of stroke and CV mortality that 
an unknown confounder would need to 
be common in the general population 
(20% prevalence), be strongly associated 
with psoriasis (odds ratio (OR) of 2.7), 
and have a stronger association with 
CV mortality (OR of 6.5) or stroke (OR 
of 4.3) than traditional CV risk factors to 
nullify our results (Gelfand et al., 2009; 
Mehta et al., 2009).
Despite the numerous recent publi-
cations investigating psoriasis and CV 
risk, fundamental questions remain 
unanswered. In particular, we do not 
know what degree of psoriasis severity 
(e.g., measured by body surface area) 
and duration are necessary to mean-
ingfully increase CV risk. We also do 
not know whether successful psoriasis 
treatment lowers CV risk and mortality 
(Gelfand, 2007; Gelfand et al., 2007). 
Until more research is done, the basic 
public health message remains the 
same. Patients with psoriasis, especial-
ly when disease is moderate to severe, 
should be educated about a poten-
tially increased risk for CV disease and 
undergo appropriate medical evaluation 
and treatment of modifiable risk factors 
(Friedewald et al., 2008; Kimball et al., 
2008; Bairey Merz et al., 2009).
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elimination of activated T cells pro-
ceeds via activation-induced cell death 
(AICD), a process that is dependent on 
Fas signaling and subsequent apoptosis. 
In the absence of adequately controlled 
AICD, T cells are likely to accumulate. 
In both mice and humans, Fas gene 
mutations leading to defective Fas sig-
naling result in lymphoproliferative 
disorders as a consequence of lympho-
cyte accumulation (Rieux-Laucat et al., 
1995). Because in certain types of CTCL 
(MF, SzS) tumor cells have been demon-
strated to be long-lived, activated CD4+ 
cells, defects in Fas-mediated apoptosis 
have recently been suggested to play a 
role in the accumulation of tumor T cells 
that occurs in each disease.
Defective Fas signaling has been 
implicated in the resistance to apopto-
sis induced by chemotherapeutic drugs. 
Furthermore, the lack of functional Fas 
signaling allows tumor cells to escape 
immune surveillance, facilitating dis-
ease progression. Several mechanisms 
contributing to Fas signaling defects in 
cancer have been described, including 
suppressed Fas expression at mRNA and 
protein levels (Bullani et al., 2002; Petak 
et al., 2003). Epigenetic silencing of the 
Fas gene promoter has been shown to 
be regulated by Ras (Gazin et al., 2007). 
Furthermore, mutations or deletions in 
Fas have been found to cause autoim-
mune lymphoproliferative syndromes 
in both mice and humans (Rieux-Laucat 
et al., 1995). Finally, the Fas signaling 
pathway can be modulated by intracel-
lular apoptosis inhibitors such as cellular 
FLICE-like inhibitory protein and Bcl-2 
family members.
Decreased expression of Fas on 
peripheral blood CD4+ T lymphocytes 
in MF and SzS was first reported in 2000 
(Dereure et al., 2000; Zoi-Toli et al., 
2000). More recently, we (Contassot et 
al., 2008) and others (Braun et al., 2007; 
Wu et al., 2009) have reported that a 
decrease, and sometimes a complete loss, 
of Fas expression is a relatively frequent 
event in lymphocytes from patients with 
SzS. In our cohort of 16 SzS patients, 9 
were resistant to FasL, which in 4 patients 
was caused by a loss of Fas expression. 
In MF, resistance to FasL-induced apop-
tosis has already been attributed to muta-
tions in the Fas gene (Dereure et al., 
2002; Nagasawa et al., 2004) and to the 
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Epigenetic Causes of Apoptosis Resistance 
in Cutaneous T-Cell Lymphomas
Emmanuel Contassot1 and Lars E. French1
In cutaneous T-cell lymphomas (CTCLs) defects in Fas-mediated apoptosis have 
been suggested to be involved in disease pathogenesis. Decreased or absent Fas 
expression has been reported in a significant proportion of CTCL patients, but 
the molecular mechanisms of such impaired Fas expression have hardly been 
investigated to date. In this issue, Jones et al. show that defective Fas expression 
is attributable to positional methylation of the Fas gene.
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Cutaneous T-cell lymphomas (CTCLs) 
are a heterogeneous group of non-
Hodgkin’s lymphomas characterized 
by the clonal proliferation of skin hom-
ing T cells. The most common CTCLs 
are mycosis fungoides (MF) and Sézary 
syndrome (SzS), an aggressive leukemic 
variant of MF. The tumor cells in MF 
and SzS exhibit a T helper type 2 (Th2) 
cytokine profile that contributes to asso-
ciated immunosuppression. Biologic 
response modifiers such as IFN-α, IFN-γ, 
and IL-12, which stimulate T helper 1 
responses, have significant therapeutic 
effects in SzS.
Appropriate Fas-mediated cell death 
is crucial for T-cell homeostasis. The 
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